International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.

International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.

M.J. Davies, D.A. D’Alessio, J. Fradkin et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12), 2461–2498 (2018)

Article  PubMed  Google Scholar 

N.A. ElSayed, G. Aleppo, V.R. Aroda et al. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023. Diabetes Care 46(Suppl 1), S140–S157 (2023)

Article  CAS  PubMed  Google Scholar 

Chinese Diabetes Society, Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin. J. Diabetes Mellitus 13(4), 315–409 (2020)

Google Scholar 

H. Kaneto, A. Takami, R. Spranger et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial. Diabetes Obes. Metab. 22(Suppl 4), 3–13 (2020)

Article  CAS  PubMed  Google Scholar 

Y. Terauchi, T. Nakama, R. Spranger et al. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial. Diabetes Obes. Metab. 22(Suppl 4), 14–23 (2020)

Article  CAS  PubMed  Google Scholar 

J. Rosenstock, M. Diamant, V.R. Aroda et al. Efficacy and safety of lixilan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: The LixiLan proof-of-concept randomized trial. Diabetes Care 39(9), 1579–1586 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Blonde, J. Rosenstock, S. Del Prato et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: The LixiLan-G randomized clinical trial. Diabetes Care 42(11), 2108–2116 (2019)

Article  CAS  PubMed  Google Scholar 

V.R. Aroda, J. Rosenstock, C. Wysham et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care 39(11), 1972–1980 (2016)

Article  CAS  PubMed  Google Scholar 

P. Home, L. Blonde, S. Kalra et al. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis. Diabetes Obes. Metab. 22(11), 2179–2188 (2020)

Article  CAS  PubMed  Google Scholar 

X. Yuan, X. Guo, J. Zhang et al. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial. Diabetes Obes. Metab. 24(11), 2182–2191 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

W. Yang, X. Dong, Q. Li et al. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial. Diabetes Obes. Metab. 24(8), 1522–1533 (2022)

Article  CAS  PubMed  Google Scholar 

J. Rosenstock, R. Emral, L. Sauque-Reyna et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial. Diabetes Care 44(10), 2361–2370 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H.S. Bajaj, L. Chu, N. Bansal et al. Randomized comparison of initiating the fixed-ratio combination of iGlarLixi or biosimilar insulin glargine together with gliclazide in participants of south asian origin with type 2 diabetes: VARIATION 2 SA trial. Can J. Diabetes 46(5), 495–502 (2022)

Article  PubMed  Google Scholar 

D. Moher, A. Liberati, J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009)

Article  PubMed  PubMed Central  Google Scholar 

A. Liberati, D.G. Altman, J. Tetzlaff et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009)

Article  PubMed  PubMed Central  Google Scholar 

S.P. Hozo, B. Djulbegovic, I. Hozo, Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol 5, 13 (2005)

Article  PubMed  PubMed Central  Google Scholar 

X. Wan, W. Wang, J. Liu et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol 14, 135 (2014)

Article  PubMed  PubMed Central  Google Scholar 

Higgins JPT, Thomas J., Chandler J., et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. Available from www.training.cochrane.org/handbook.

J. Rosenstock, R. Aronson, G. Grunberger et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diabetes Care 39(11), 2026–2035 (2016)

Article  CAS  PubMed  Google Scholar 

M.J. Lage, K.S. Boye, The relationship between HbA1c reduction and healthcare costs among patients with type 2 diabetes: evidence from a U.S. claims database. Curr Med Res Opin 36(9), 1441–1447 (2020)

Article  CAS  PubMed  Google Scholar 

R.R. Holman, S.K. Paul, M.A. Bethel et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359(15), 1577–1589 (2008)

Article  CAS  PubMed  Google Scholar 

D.M. Nathan, M. Bayless, P. Cleary et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes 62(12), 3976–3986 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

R.J. McCrimmon, M. Lamotte, M. Ramos et al. Cost-effectiveness of iGlarLixi Versus iDegLira in type 2 diabetes mellitus inadequately controlled by GLP-1 receptor agonists and oral antihyperglycemic therapy. Diabetes Ther. 12(12), 3231–3241 (2021)

Article  CAS  PubMed  PubMed Central  Google Scholar 

K.M. Pantalone, C. Heller, R. Lajara et al. Initiation of iGlarLixi versus basal-bolus insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study. Diabetes Spectr 36(3), 253–263 (2023)

Article  PubMed  PubMed Central  Google Scholar 

S. Edelman, D. Cassarino, D. Kayne et al. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J. Manag. Care Spec. Pharm. 28(9), 958–968 (2022)

PubMed  Google Scholar 

M. Munshi, R. Ritzel, E.B. Jude et al. Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials. Diabetes Obes. Metab. 26(3), 851–859 (2024)

Article  CAS  PubMed  Google Scholar